Chris Stevens

Chris has a passion for synthetic organic chemistry with a particular focus on bioactive small molecules and pharmaceutical technology (e.g., continuous flow synthesis). His work led to several patents which are now being exploited in companies such as CreaChem, Amphistar, Q-Pinch and Amalus Therapeutics.

Chris Stevens is the CEO of Amalus Therapeutics and Full Professor of Bio-Organic Chemistry at Ghent University, Belgium. He holds a PhD in Bioengineering (Ghent University, Belgium) and a Postgraduate in Managerial Economics (KULeuven, Belgium). He has built up managerial experience as Head of Department and Member of the Board of Flanders' Food. He is currently Faculty Member and Member of the Board of Directors of Ghent University. Chris is Fellow of the Royal Society of Chemistry (UK) and Member of the Royal Flemish Academy of Belgium for Science and the Arts.